CytomX Therapeutics
CTMX
67 hedge funds and large institutions have $58.7M invested in CytomX Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 12 closing their positions.
350% more call options, than puts
Call options by funds: $81K | Put options by funds: $18K
9% more capital invested
Capital invested by funds: $53.7M → $58.7M (+$5.02M)
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
2.23% less ownership
Funds ownership: 53.67% → 51.43% (-2.2%)
11% less funds holding
Funds holding: 75 → 67 (-8)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$842K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$571K |
| 3 |
Renaissance Technologies
New York
|
+$452K |
| 4 |
Squarepoint
New York
|
+$225K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$642K |
| 2 |
Two Sigma Investments
New York
|
-$546K |
| 3 |
Millennium Management
New York
|
-$518K |
| 4 |
Two Sigma Advisers
New York
|
-$476K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$448K |
CTMX Hedge Fund Activity: Q2 2023 in Review
67 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2023, worth a combined $58.7M — up 9.3% from $53.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CTMX and 4 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 20 added.
The largest buyer was Tang Capital Management, adding an estimated $842K. The largest seller was Newtyn Management, exiting entirely with an estimated $642K sold.
- 67 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2023, down from 75 in Q1 2023.
- Funds reported $58.7M of CytomX Therapeutics stock for Q2 2023, up 9.3% quarter-over-quarter.
- 4 funds opened new CytomX Therapeutics positions in Q2 2023 and 12 closed out, a net change of -8 holders.
- The largest CytomX Therapeutics buyer in Q2 2023 was Tang Capital Management, an estimated $842K added.
- The largest CytomX Therapeutics seller in Q2 2023 was Newtyn Management, an estimated $642K sold.
Based on aggregated 13F filings for Q2 2023.